AG真人官方

Data Storage Corp. (DTST/DTSTW) filed a Schedule TO-C disclosing plans for an issuer tender offer that will begin only after shareholders approve the proposed divestiture of the company鈥檚 cloud solutions business at the 10 Sep 2025 annual meeting. If the sale closes, the company intends to deploy 85 % of its cash on hand鈥攊ncluding the net divestiture proceeds鈥攖o repurchase up to 85 % of every shareholder鈥檚 common shares, potentially removing a large portion of the float.

The filing is strictly a pre-commencement communication; no price, timing or proration terms are yet available. Formal tender documents (Offer to Purchase, Letter of Transmittal, etc.) will be filed later on Schedule TO and provided free via the SEC and the company website. Until then, this notice is neither an offer to buy nor a solicitation to sell shares.

Advanced Biomed Inc. (Nasdaq: ADVB) has filed a Form S-1 covering up to 40 million common shares that may be issued to and resold by Helena Global Investment Opportunities I Ltd. under a $25 million equity line of credit (ELOC) signed 6 Jun 2025. The company can draw capital at its discretion, but each draw will be priced at a discount to the prevailing market, creating potential dilution. Helena will also receive commitment-fee shares valued at $500,000, calculated on a volume-weighted price at the earlier of six months after signing or SEC effectiveness.

ADVB will receive no proceeds from resale by Helena; cash raised from primary issuances will fund R&D and working capital. The S-1 warns that substantial share issuances could depress the stock price and that the offering may be deemed 鈥渁t-the-market鈥� under Rule 415.

Risk highlights: (1) Nasdaq issued a minimum-bid-price deficiency notice on 18 Jul 2025; ADVB has until 14 Jan 2026 to regain compliance or face delisting. (2) Although headquartered in Taiwan, the company has a Shanghai subsidiary and is exposed to evolving PRC oversight of data security and overseas listings, which could impair operations or value. (3) ADVB is pre-revenue, expects continuing losses and depends on regulatory clearance of its liquid-biopsy devices; only two products (A+Pre, AC-1000) have obtained NMPA clearance so far.

ADVB qualifies as an Emerging Growth Company and will bear registration costs but not brokerage fees for selling stockholder transactions.

Paychex Inc. (PAYX) 鈥� Form 5 Annual Statement of Changes in Beneficial Ownership

The filing reports the end-of-fiscal-year (31 May 2025) equity holdings of Mark Anthony Bottini, Senior Vice President of Sales. No new insider transactions are listed for the period; the document only updates cumulative ownership.

• Direct common-stock holding: 79,360 shares
• Indirect holding: 1,772 shares through the company 401(k) plan
• Employee Stock Purchase Plan (ESPP): 36 shares
• Outstanding stock options: 383,887 options across ten grants with strike prices ranging from $57.24 to $121.63 and expiration dates from July 2026 to July 2034

The absence of reported acquisitions or dispositions suggests that Mr. Bottini neither bought nor sold PAYX shares during FY 2025 under Section 16 reporting rules. His sizable equity and option position continues to align management incentives with shareholder interests, but the filing itself does not signal an operational or financial change for the company.

JPMorgan Chase Financial Company LLC is marketing Contingent Income Callable Securities (principal at risk) due July 15, 2027. Payments are based on the worst-performing of three equity benchmarks: the EURO STOXX 50 (SX5E), S&P 500 (SPX) and Russell 2000 (RTY).

Key structural terms

• Stated principal: $1,000 per note.
• Tenor: roughly two years (pricing expected July 11, 2025; maturity July 15, 2027).
• Contingent coupon: at least 2.275% quarterly (鈮� 9.1% p.a.) paid only if each index closes 鈮� 70 % of its initial level on every day in the relevant monitoring period.
• Downside threshold / barrier: 70 % of each index鈥檚 initial level.
• Early redemption: Issuer may call the notes in whole (not in part) on any coupon payment date after the first, paying principal + any due coupon.
• Payment at maturity (if not called):
  • If every index final level 鈮� barrier: return of principal plus final coupon (subject to daily tests).
  • If any index final level < barrier: redemption value = principal 脳 (worst index final/initial). Investors can receive <70 % of par and down to zero.
• Estimated value: approximately $962.50 per $1,000 (final figure will be 鈮� $940).
• Fees: $15 selling concession and $4.286 structuring fee per note, embedded in the $1,000 issue price.
• Credit: senior unsecured obligations of JPMorgan Chase Financial Co. LLC, fully and unconditionally guaranteed by JPMorgan Chase & Co.
• Listing: none; secondary liquidity expected to be limited and dealer-driven.

Risk highlights

• No principal protection; investors are exposed 1-for-1 to downside of the worst-performing index below the 70 % barrier.
• Coupons are contingent; a single index breach on any day in a quarter cancels that quarter鈥檚 payment.
• Issuer call risk: JPMorgan is most likely to redeem when the notes are performing well, capping upside and forcing reinvestment risk.
• Credit risk of both the issuer and guarantor.
• Estimated value is below issue price; secondary prices will reflect dealer funding spreads, hedging costs and bid-ask spreads.

The product suits investors seeking high conditional income and willing to assume equity-index, barrier and issuer-call risks, acknowledging the possibility of losing the entire principal.

JPMorgan Chase Financial Company LLC is marketing Callable Contingent Interest Notes linked to the Class A common stock of Palantir Technologies Inc. (PLTR), fully guaranteed by JPMorgan Chase & Co. The unsecured notes mature on 14 January 2027 and offer a monthly contingent coupon of at least 2.33333% (鈮�28.00% p.a.) whenever the Palantir share price on the relevant 18 Review Dates is at or above the 60% Interest Barrier/Trigger Value established on the pricing date (鈮�11 July 2025).

Early redemption: JPMorgan may call the notes in whole on any Interest Payment Date from 16 October 2025 onward (except the final date). If called, investors receive par plus the coupon for the prior Review Date, truncating future coupons.

Principal at risk: If the notes are not called and the Final Value of PLTR on the last Review Date falls below the 60% Trigger, repayment equals $1,000 脳 (1 + Stock Return), exposing investors to losses of more than 40% and potentially 100% of principal. Investors do not participate in any upside beyond the coupons.

Key economics (illustrative): 鈥� Estimated value if priced today: $970.80 per $1,000 note (final estimate will not be below $900). 鈥� Selling commissions 鈮� $6.50 per $1,000. 鈥� Hypothetical total coupon if all 18 payments made: $420 (42% of par). 鈥� Minimum denomination: $1,000.

Risk highlights (as disclosed):

• No guaranteed coupons; missed if PLTR closes <60% of initial on a Review Date.
• Principal loss below the Trigger at maturity.
• Issuer and guarantor credit risk; the notes are senior unsecured obligations.
• Potential liquidity constraints鈥攏o exchange listing and secondary pricing at JPMS discretion, likely below par.
• Early call risk may reinvestment risk and limits maximum return.
• Estimated value below issue price reflects selling, structuring and hedging costs.

These notes suit investors comfortable with single-stock volatility, credit exposure to JPMorgan, and the possibility of no coupon and significant principal loss in exchange for an elevated contingent yield.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) has filed a Form S-1 to register 6,355,650 shares of common stock for resale by existing holders. The bulk of the shares (6,053,000) are issuable upon exercise of Series G common warrants at an exercise price of $0.6954 per share (first exercisable 28 Sep 2025; expire 28 Mar 2033). A further 302,650 shares relate to warrants issued to placement agent Ladenburg Thalmann at $0.8125 per share (same first exercise date; expire 28 Sep 2030).

The company will not receive proceeds from the resale; cash would only be generated if warrant holders exercise for cash. At the last reported price of $0.2339 (2 Jul 2025) the warrants are out-of-the-money, but their future exercise could raise capital and dilute existing holders.

Calidi remains an emerging growth and smaller reporting company. It is also seeking shareholder approval to implement a reverse stock split between 1-for-2 and 1-for-19, after which historical share data will be adjusted.

Business profile. Calidi is a clinical-stage biotech developing three immuno-oncology platforms: RedTail (engineered vaccinia virus for systemic delivery of genetic medicines), SuperNova and NeuroNova (stem-cell-based oncolytic virus platforms). Lead candidate CLD-401 (IL-15 super-agonist payload) is targeted to enter Phase I by end-2026. The company currently has no approved products or revenue and highlights the need for substantial additional funding.

Governance changes. Former CEO & Chairman Allan Camaisa resigned effective 22 Apr 2025, becoming 鈥淐EO Emeritus鈥� and remaining a Class III director. Eric Poma, Ph.D. was appointed CEO and Class I director, and James Schoeneck became Chairman. Camaisa receives a $500,000 12-month separation package plus consulting and COBRA payments.

The prospectus reiterates extensive risk factors typical of early-stage biotech firms, including capital needs, clinical uncertainty and potential NYSE American listing compliance.

On June 30, 2025, Xenon Pharmaceuticals Inc. (XENE) filed an 8-K announcing a leadership change under Item 5.02. Chief Financial Officer Sherry Aulin resigned the same day. The Board appointed current President & CEO Ian Mortimer as interim CFO, making him the company鈥檚 principal financial and accounting officer effective immediately. No modifications were made to Mortimer鈥檚 compensation package. Required biographical and related-party information for Mr. Mortimer was previously disclosed in Xenon鈥檚 April 24, 2025 proxy statement and is incorporated by reference. No other material transactions or financial data were included in the filing.

The dual CEO/CFO role is intended to be temporary, but the company did not specify the duration of the interim arrangement or outline a search process for a permanent CFO.

GS Finance Corp. is offering $1.08 million of Autocallable Contingent Coupon Equity-Linked Notes due 2028, fully and unconditionally guaranteed by The Goldman Sachs Group, Inc. The notes are tied to the performance of Palantir Technologies Inc. (PLTR) Class A common shares and form part of Goldman鈥檚 Series F medium-term note program.

Key commercial terms

• Face amount: $1,000 per note (aggregate $1.08 million)
• Issue price: 100% (trade date 30-Jun-2025; settlement 03-Jul-2025)
• Quarterly contingent coupon: $69.625 (6.9625% per quarter, up to 27.85% p.a.) payable only if PLTR closes at or above 60% of the initial price ($136.32) on the relevant observation date.
• Automatic call: If PLTR closes at or above the initial price on any quarterly call observation date from Sep-2025 to Mar-2028, the notes are redeemed at par plus the due coupon.
• Downside protection: 40% buffer. If the final price on 30-Jun-2028 is 鈮�60% of the initial price, holders receive par plus any final coupon. If below 60%, repayment equals par plus (index return 脳 par), exposing investors to full downside beyond the buffer.
• Estimated value at pricing: ~$970 per $1,000, reflecting structuring fees and dealer margin; underwriting discount 2%.
• Secondary market: GS & Co. may, but is not obliged to, make a market; bid/ask reflects estimated value plus declining premium (initially $25).
• Credit: senior unsecured obligation of GS Finance Corp. with unconditional guarantee from The Goldman Sachs Group, Inc.; not FDIC insured.

Risk highlights

• Investors may receive no coupons if PLTR trades below the 60% trigger on observation dates.
• If PLTR falls >40% at maturity and the note hasn鈥檛 been called, principal loss is one-for-one with the stock鈥檚 decline.
• Limited upside: maximum redemption is par plus due coupon; investors do not participate in stock gains above par.
• Market value likely to be below issue price; liquidity limited; pricing sensitive to GS credit spreads, PLTR volatility and interest rates.
• Product complexity, dilution events, market disruption adjustments and discretionary determinations by GS & Co. add additional risks.

The prospectus supplement also details anti-dilution adjustments, default provisions, tax characterization (income-bearing prepaid derivative contract) and extensive hypothetical scenarios illustrating coupon and principal outcomes.

Event: On June 27, 2025, Banzai International, Inc. (NASDAQ: BNZI) filed a Form 8-K disclosing the results of a special shareholder meeting held the same day.

Key outcome: Shareholders approved an amendment to the Company鈥檚 Second Amended and Restated Certificate of Incorporation authorizing a 1-for-10 reverse stock split of both Class A and Class B common stock. The Board of Directors retains the authority to abandon the action if it later deems the split unnecessary.

Voting details:

• For: 25,320,879 votes
• Against: 242,880 votes
• Abstained: 4,919 votes

Quorum: 4,768,472 Class A shares (24.34% voting power) and 25,568,678 Class B shares (63.31% voting power) were represented by proxy, establishing a quorum and eliminating the need to adjourn the meeting.

Next steps: Because the proposal passed, the Company intends to file a Certificate of Amendment with the Delaware Secretary of State to implement the reverse split. No other business items, financial results, or major transactions were disclosed in this filing.